Home
Live Updates
Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 : comparemela.com
Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
Related Keywords
Dublin ,
Ireland ,
Massachusetts ,
United States ,
Houston ,
Texas ,
Ohio ,
Craig Hopkinson ,
Gretchen Murphy ,
Michaelj Doane ,
Davidt Plante ,
Ron Grunstein ,
Sandy Coombs ,
University Of Wisconsin ,
Alkermes ,
Group Study Evaluating The Safety ,
Research Development At Alkermes ,
Woolcock Institute Of Medical Research ,
World Sleep Congress ,
Nasdaq ,
Circadian Research ,
Breaking Abstracts Containing Data From ,
Full Narcolepsy Type ,
Design Accepted ,
Poster Presentations ,
From In Depth Qualitative Patient Interviews ,
Narcolepsy Will Also Be Presented ,
Associated Professional Sleep Societies ,
Wakefulness Test ,
Karolinska Sleepiness Scale ,
Chief Medical Officer ,
Executive Vice President ,
Pharmacodynamic Effects ,
Narcolepsy Type ,
First In Human Phase ,
Board Number ,
Woolcock Institute ,
Study Design ,
Parallel Group Study Evaluating ,
Patients With Narcolepsy Type ,
Associate Professor ,
Patient Perspectives ,
In Depth Qualitative ,
Selective Orexin Receptor ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.